BXCXClinical Trials•globenewswire•
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
Sentiment:Negative (10)
Summary
Company to host conference call at 8 a.m. ET, August 27, 2025 Company to host conference call at 8 a.m. ET, August 27, 2025
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by globenewswire